PhytoGaia, a palm phytonutrient specialist and Monash University have signed a Memorandum of Agreement (MOA), which marks the initiation of a clinical trial aiming to study the effectiveness of STGaia for skin health and anti-ageing purposes.
STGaia contains two synergistic active compounds — natural squalene and tocotrienols — in a complex, which was developed specifically to target the ill effects of dry skin.
The study
The trial, entitled: ‘Alterations in Skin Hydration, Moisture and Genomic in Subjects with Dry Skin Conditions following Daily Oral Palm Tocotrienol and Squalene ( STGaia ) Supplementation,’ aims to uncover the potential benefits of STGaia for individuals struggling with dry skin that’s showing signs of ageing.
The primary objective of this randomised, placebo-controlled trial (RCT) is to investigate the effects of dietary supplementation with STGaia, an exclusive product from PhytoGaia on human subjects with dry, scaly and itchy skin.
The clinical trial will evaluate the impact of STGaia supplementation on skin hydration, moisture levels and the expression of genes associated with skin health among study participants.
“By leveraging on the expertise of Monash University’s researchers, we aim to uncover valuable insights into the efficacy of STGaia and its potential to enhance the lives of individuals dealing with dry skin conditions and age-related concerns.” remarked Mr Bryan See, Vice President at PhytoGaia.
“The nutrigenomic analyses will provide a comprehensive understanding of how STGaia supplementation influences gene expression and skin health at the molecular level, which has not been done before”.
This human clinical trial is also anticipated to further stimulate the interest and investment in clinical research within Malaysia — especially for palm-based phytonutrients — an important downstream commercial activity for Malaysia’s palm oil industry.
